Every number, back to a public source.

Our trial registry of record — we read it for site density, where studies in your indication are actually running, and the competitive trial landscape.

Registry of public and private clinical studies worldwide — enrollment, status, sponsors, sites, and outcomes.

The literature backbone — we use it to ground indication baselines, endpoint precedent, and the evidence that feeds PTRS scoring.

Biomedical literature index of 36M+ citations — used to ground indication baselines and standard-of-care evidence.

U.S. approvals, labels, and adverse-event signals — we use it to anchor regulatory-uplift estimates and molecule-level safety risk.

Approvals, labels, guidance, and adverse-event signals (openFDA) used to anchor regulatory-uplift and safety risk.

EU approvals and scientific guidance (EPARs) — we use it to model the European regulatory pathway and country-level benchmarks.

European approvals, EPARs, and scientific guidance used to model EU regulatory pathways and country benchmarks.

Target–disease association evidence — we use it as the basis for probability-of-success (PTRS) scoring and target tractability.

Target–disease association evidence integrating genetics, pathways, and known drugs — feeds PTRS scoring.

A structured, queryable mirror of ClinicalTrials.gov — it is the analytical engine behind our cohort, enrollment-velocity, and investigator-history statistics.

Relational, queryable database of all ClinicalTrials.gov content — the analytical backbone for site and enrollment statistics.

A curated bioactivity database — we use it to characterise molecule risk and mechanism precedent from the chemistry and target side.

Manually curated bioactivity database of drug-like molecules — used to characterize molecule risk and mechanism precedent.